Lead Product(s): Tibolone
Therapeutic Area: Musculoskeletal Product Name: Tibelia
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Spirig Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 11, 2020
Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein and Switzerland.